Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Alexandre Harlé

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9548-6522; OpenAlex author ID A5003880256. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 4 papers

Papers 12

  1. Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. Last author DOI 10.1016/j.ijrobp.2025.09.013↗
  2. Radiotherapy in the management of PDAC, from past to present. Last author DOI 10.1016/j.tranon.2025.102632↗
  3. Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG … Co-author DOI 10.1097/sla.0000000000006449↗
  4. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Last author DOI 10.1200/jco-25-02508↗
  5. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  6. DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. Last author DOI 10.1038/s41420-024-02188-9↗
  7. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  8. CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines. Last author DOI 10.1038/s41598-023-45964-w↗
  9. DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. Co-author DOI 10.3389/fonc.2022.1052163↗
  10. Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial. Co-author DOI 10.3390/cancers14205068↗
  11. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Last author DOI 10.3390/ph14080740↗
  12. SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/ijms21103534↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aurélien Lambert · 9 shared papers, 2022–2026 · strength 1.91
  2. Andréa Witz · 8 shared papers, 2020–2026 · strength 1.64
  3. Pauline Gilson · 7 shared papers, 2020–2026 · strength 1.41
  4. Julie Dardare · 7 shared papers, 2020–2026 · strength 1.41
  5. Thierry Conroy · 5 shared papers, 2022–2026 · strength 0.98
  6. James Biagi · 4 shared papers, 2024–2026 · strength 0.83
  7. Jerome F. Cros · 4 shared papers, 2024–2026 · strength 0.83
  8. Rémy Nicolle · 3 shared papers, 2024–2026 · strength 0.55
  9. Anthony Turpin · 3 shared papers, 2024–2026 · strength 0.55
  10. Daniel John Renouf · 3 shared papers, 2024–2026 · strength 0.55
  11. Juan Iovanna · 3 shared papers, 2024–2026 · strength 0.55
  12. Pascal R. Hammel · 3 shared papers, 2024–2026 · strength 0.55
  13. Jean‐Baptiste Bachet · 3 shared papers, 2024–2026 · strength 0.55
  14. Nelson Dusetti · 3 shared papers, 2024–2026 · strength 0.55
  15. Emmanuel Mitry · 2 shared papers, 2024 · strength 0.32
  16. Vinciane Rebours · 2 shared papers, 2024 · strength 0.32
  17. Alice Chia-Chi Wei · 1 shared paper, 2024 · strength 0.16
  18. Éric François · 1 shared paper, 2024 · strength 0.16
  19. Valérie Laurent · 1 shared paper, 2022 · strength 0.16
  20. Julie Egea · 1 shared paper, 2022 · strength 0.16
  21. Eric Assénat · 1 shared paper, 2024 · strength 0.15
  22. Nicolas Alejandro Fraunhoffer · 1 shared paper, 2024 · strength 0.15
  23. Brice Chanez · 1 shared paper, 2024 · strength 0.15
  24. Olivier Bouché · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.